期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 18, 期 47, 页码 6876-6884出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v18.i47.6876
关键词
Human embryonic stem cells; Induced pluripotent stem cells; Mesenchymal stem cells; Beta cell differentiation; Reprogramming; Islet transplantation
资金
- National Institutes of Health
- Juvenile Diabetes Research Foundation
- American Diabetes Association
- Foundation for Diabetes Research
- Diabetes Research Institute Foundation
If only at a small scale, islet transplantation has successfully addressed what ought to be the primary end-point of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-than-optimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell lineage and the direct reprogramming of non-endocrine tissues into insulin-producing cells. (C) 2012 Baishideng. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据